Diogo Pinto

At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.

Articles by Diogo Pinto

MYELOMA

Surface Oncology’s SRF231 Granted Orphan Drug Status for Treatment of Multiple Myeloma

SRF231, an experimental anti-CD47 immunotherapy candidate developed by Surface Oncology, was granted orphan drug status by the U.S.